Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.

Marks, William J

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. [electronic resource] - The Lancet. Neurology May 2008 - 400-8 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

1474-4422

10.1016/S1474-4422(08)70065-6 doi


Adult
Aged
Dependovirus--physiology
Dose-Response Relationship, Drug
Drug Delivery Systems
Female
Genetic Therapy--methods
Genetic Vectors--physiology
Humans
Male
Middle Aged
Motor Activity--drug effects
Neurturin--biosynthesis
Parkinson Disease--pathology
Putamen--drug effects